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Abstract
Background: Spinal muscular atrophy (SMA) is an autosomal recessive disorder that affects the motoneurons of
the spinal anterior horn, resulting in hypotonia and muscle weakness. The disease is caused by deletion or
mutation in the telomeric copy of SMN gene (SMN1) and clinical severity is in part determined by the copy
number of the centromeric copy of the SMN gene (SMN2). The SMN2 mRNA lacks exon 7, resulting in a production
of lower amounts of the full-length SMN protein. Knowledge of the molecular mechanism of diseases has led to
the discovery of drugs capable of increasing SMN protein level through activation of SMN2 gene. One of these
drugs is the valproic acid (VPA), a histone deacetylase inhibitor.
Methods: Twenty-two patients with type II and III SMA, aged between 2 and 18 years, were treated with VPA and
were evaluated five times during a one-year period using the Manual Muscle Test (Medical Research Council scale-
MRC), the Hammersmith Functional Motor Scale (HFMS), and the Barthel Index.
Results: After 12 months of therapy, the patients did not gain muscle strength. The group of children with SMA
type II presented a significant gain in HFMS scores during the treatment. This improvement was not observed in
the group of type III patients. The analysis of the HFMS scores during the treatment period in the groups of
patients younger and older than 6 years of age did not show any significant result. There was an improvement of
the daily activities at the end of the VPA treatment period.
Conclusion: Treatment of SMA patients with VPA may be a potential alternative to alleviate the progression of the disease.
Trial Registration: ClinicalTrials.gov: NCT01033331
Background
Spinal muscular atrophy (SMA) is an autosomal recessive
neurodegenerative childhood disease characterized by loss
of lower motor neurons in the anterior horn cells in the
spinal cord and brainstem, causing progressive proximal
symmetrical weakness and atrophy of skeletal muscle. It is
the most common inherited neuromuscular diseases of
childhood with a prevalence of 1 in 6,000 to 10,000 [1,2].
SMA has been classified clinically into four types based on
age of onset and maximum function attained [3]. Type I
SMA, Werdnig-Hoffmann disease, is characterized by
onset within the first 6 months of age, and the children
never achieve the ability to sit without support. Type II
SMA is characterized by onset of muscle weakness and
hypotony usually after six months of age; the children are
able to sit but unable to walk unaided. In the type III
SMA, Kugelberg-Welander disease, the initial manifesta-
tions usually occurs after 18 months of age; and the
patients achieves the ability to walk. Type IV SMA is a
mild form with an adult onset of muscle weakness. All
four types of SMA show a progressive course, which is
severe in type I and mild in type III and IV SMA [4].
Approximately 95%-98% of individuals with a clinical
diagnosis of SMA lack exon 7 in both copies of SMN1
gene, while approximately 2%-5% of them are compound
heterozygotes for deletion of SMN1 i no n ea l l e l ea n da n
intragenic mutation of SMN1 in another allele [5,6]. The
human SMN gene is located at the chromosome 5 (5q),
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telomeric copy and produces a full-length survival motor
neuron (SMN) protein necessary for a normal lower
motor neuron function [5]. The centromeric SMN2 copy
mostly encodes a protein that is lacking in exon 7 due to
alternative splicing, thereby producing a less stable pro-
tein. The amount of functional SMN protein produced by
SMN2 is not sufficient to prevent the progressive degen-
eration of motor neuron when SMN1 is absent. The
SMN2 gene copy number is variable, ranging from zero to
five. Several studies have demonstrated a strong inverse
correlation between the number of SMN2 copies and
SMA severity [7-11]. The presence of three or more copies
of SMN2 is correlated with a milder phenotype [9-11].
Thus, SMN2 activation and/or modulation of the SMN2
splicing pattern have been used as a strategy for SMA
treatment to increase full length SMN protein level.
The modulation of SMN2 expression is in part con-
trolled by acetylation and deacetylation of histones in the
promoter region. Thus, the inhibitors of histone deacety-
lases (HDAC), such as phenylbutyrate and valproic acid
(VPA), could promote the acetylation of the DNA increas-
ing the gene expression and the level of full-length SMN
protein [12]. Many studies have demonstrated that phenyl-
butyrate, a drug used in the treatment of urea acid cycle
disorders, and VPA increase SMN2 transcripts and full-
length SMN protein in different types of cells from
patients and in animal models of SMA [13-16]. Prelimin-
ary clinical trials have studied the preclinical stages of
research in animal models or in vitro experiments [17-22].
Brichta et al [17] observed an increase of 13 times in the
blood level of full length SMN proteins in seven SMA chil-
dren treated with VPA. An improvement in seven adult
patients with SMA type III and IV during treatment with
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observed significant increase of the overall strength in type
II SMA treated with VPA during six months. In an open
label study, Swoboda et al [20] assessed 42 SMA indivi-
duals treated with VPA during 12 months, and observed a
significant improvement almost restricted to participants
aged less than 5 years. More recently, Swoboda et al [21]
assessed 61 subjects randomized 1:1 to placebo or treat-
ment with VPA and L-carnitine for six months, but no
benefit was demonstrated. Thus, the clinical efficacy of
VPA in patients with SMA is still controversial. In this
study, we quantified the muscular strength and motor
function of patients with SMA type II and III treated with
VPA and assessed the side effects of the medication.
Methods
Study design
We included in this study 35 patients with SMA type II
and III confirmed by molecular analysis, aged between 2
to 18 years old, regularly treated at the Out-patient
Service Center for Neuromuscular Disorders and Child
Neurology at our Institution. This open, comparative and
longitudinal study had the approval of the Ethical Com-
mittee for Project and Research; and the parents or legal
guardians signed an informed consent form for partici-
pating in the study. The patients were evaluated five
times during one year by the same examiners: PGP (phy-
sician) and IAD (physical therapist). The first evaluation
was done just before the prescription of VPA, and the
following assessments were carried out at three, six, nine
and twelve months after theo n s e to fV P At h e r a p y .A l l
patients received 20 mg/Kg/day of VPA (divided into 2
or 3 doses), L-Carnitine (100 mg/Kg/day) and vitamin
supplement. Laboratory tests were performed before the
beginning of the treatment and after 6 and 12 months,
and included the measurement of blood cells, hepatic
and pancreatic enzymes and serum level of VPA.
Muscular strength and functional assessment
Patients were evaluated using the following methods: 1)
The Hammersmith Functional Motor Scale (HFMS),
which includes 20 items scored from 0 to 40 [23]; 2) the
Medical Research Council (MRC) method for testing
the muscular strength of the main muscular groups
(flexion and extension of shoulders, hips, elbows, wrists,
knees, feet and trunk; abduction and adduction of
shoulders and hip), scored from 0 to 5 points [24]; and
3) the Barthel Index for evaluating the daily activities in
patients older than 5 years of age [25].
Statistical analysis
We used the ANOVA test to compare both the averages
by time and groups. The Pearson product-moment corre-
lation coefficient was calculated with its interval at 95%
(IC 95%) to analyze the relation between the interested
variables.
Results
Among the thirty-five patients with SMA, five did not
return regularly to the appointments and eight did not
take the drug according to the medical prescription. Thus,
only 22 patients, aged between 2 and 18 years (mean =
5.5), 14 SMA type II (63.6%) and 8 type III (36.4%), com-
pleted the period of the study (Table 1). In all 22 patients
the serum concentration of VPA was between 40-100 mg/
dL in the period of the study. No patient displayed any sig-
nificant change in laboratory tests performed during the
period of follow-up. Five patients developed a worsening
of prior hand tremors, and three patients had their body
mass index (BMI) increased during the treatment, but not
reaching the overweight category.
Muscle strength, the HFMS and the Barthel index
The comparison between the MRC mean in the first
evaluation and in subsequent ones did not show any
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of all 22 patients together showed a significant differ-
ence in the HFMS scores comparing the first with the
s e c o n da n dt h ef o u r t he v a l u a t i o n s( p=0 . 0 3 8a n dp=
0.039, respectively), but not in the third and fifth evalua-
tions. The group of children with SMA type II presented
a significant gain in HFMS score comparing the first
evaluation with the subsequent ones (p = 0.031)
(Table 3). This gain in HFMS score was not observed in
the group of type III patients (p = 0.961). Patients
younger than six years of age had a better mean score
on HFMS than the group older than six years of age
(Table 4). However, the comparison of the HFMS score
of the first evaluation with the subsequent ones in the
groups of patients younger and older than 6 years of age
did not show any significant result (p = 0.240 and p =
0.922, respectively) (Table 4). According to the Table 2,
there was a significant difference when comparing the
mean of the Barthel score of the first evaluation with
t h ef o u r t ha n df i f t he v a l u a t i o ns, indicating an improve-
ment of the daily activities at the end of the VPA treat-
ment period.
Discussion
Our present study demonstrated that there was not any
evident motor function deterioration during the period
of one year of treatment with VPA in patients with
SMA type II and III. We did not detect any significant
change in muscular strength tested using the MRC
scale. However, we observed a significant improvement
in the motor abilities assessed by HFMS, a scale that
was structured and validated specifically for evaluating
children with SMA [23]. When all 22 patients were ana-
lyzed together, the comparison of the first HFMS score
with the following ones showed a significant improve-
ment only in the second and fourth evaluations, but not
in the third and fifth ones, suggesting that treatment
with VPA might produce variable pick of action.
Table 1 General data from 22 patients with SMA treated with VPA
Case Age/sex SMA type Age at diagnosis Maximal motor ability Procedures
1 9y/F II 8y Sits ——————————
2 3y/F II 1y Sits ——————————
3 5y/M III 4y Walks independently ——————————
4 6y/M III 2y Walks independently ——————————
5 18y/F III 4y Walks independently ——————————
6 3y/F II 1y Sits ——————————
7 13y/M III 4y Walks independently ——————————
8 2y/F III 2y Walks independently ——————————
9 6y/M II 3y Stand up with support Foot and spinal orthesis
10 5y/M II 10 mo Sits —————————
11 15y/F II 2y Sits Back surgery
12 5y/M III 4y Walks independently —————————
13 13y/F II 3y Sits Back surgery
14 3y/F III 8 mo Walks independently —————————
15 3y/M II 1y Sits with support —————————
16 8y/M III 1y Walks independently —————————
17 15y/F II 2y Sits Back and hip surgery
18 3y/F II 8 mo Sits Spinal orthesis
19 11y/M II 1y Sits Foot orthesis
20 2y/M II 2y Sits with support Foot orthesis/BiPAP
21 4y/M III 1y Walks independently Foot orthesis
22 16y/M II 7y Sits with support ——————————————————
F = female, m = male, y = year, mo = months.
Table 2 Comparison between the mean of the MRC, HFMS and Barthel index scores in the first evaluation and the
subsequent evaluations in the 22 SMA patients treated with VPA
Evaluation MRC HFMS Barthel
1 × 2 -0.0 ± 0.4 (p = 0.999) -0.8 ± 0.4 (p = 0.038) -0.0 ± 0.7 (p = 0.999)
1 × 3 -0.1 ± 0.6 (p = 0.947) -1.0 ± 0.5 (p = 0.056) -1.3 ± 0.9 (p = 1.53)
1 × 4 -0.4 ± 0.7 (p = 0.600) -1.4 ± 0.6 (p = 0.039) -2.3 ± 1.1 (p = 0.043)
1 × 5 -1.0 ± 0.8 (p = 0.267) -1.4 ± 0.7 (0.063) -2.7 ± 1.3 (p = 0.045)
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type III) were analyzed separately, there was a significant
gain on HFMS score comparing the first evaluation with
the subsequent ones only in the SMA type II group.
The major limitation of our study was the non inclu-
sion of a control group. Despite suffering from a pro-
gressive neurodegenerative disease, patients with SMA
type II/III may show short term improvement of their
motor status, in which it could be influenced by many
factors including physical therapy, mental status and
systemic diseases. However, in the period of evaluation,
we could observe that no patient presented deterioration
of their motor function, in which it would be expected
considering the progressive course of the disease.
In our study, we did not perform SMN2 mRNA level
analysis. However, studies assessing SMN mRNA levels
in treated patients with VPA have demonstrated con-
flicting results. Brichta eta l[ 1 7 ]o b s e r v e de l e v a t e d
SMN2 mRNA levels in seven patients with SMA treated
with VPA and unchanged or decreased levels in thirteen
patients. Swoboda et al [20] did not show any significant
increase of SMN2 mRNA levels in children treated with
VPA, although the level of mRNA fluctuated throughout
VPA treatment, in contrast with untreated patients in
which the level was fairly stable, indicating that at least
some response to the VPA treatment was obtained.
In this study we included only SMA patients with types
II and III, avoiding the inclusion of the most severe form
of the disease (type I). However, unfortunately we did not
measure the SMN2 copy number in our patients that
would be very interesting to divide the patients in more
homogeneous groups and for a better comparison of our
results with future studies.
According to Swoboda et al [26] the best potential gain
from therapeutic intervention, if any, should be more
probable in pre-clinic phases when the children have a
large number of still healthy motor neurons, thereby
allowing for more benefits. Swoboda et al (2009) [20]
showed a significant improvement that was almost
restricted to participants less than 5 years of age follow-
ing VPA treatment in 42 patients with SMA. In our
study, patients younger than six years of age had a better
mean score on HFMS than the group older than six years
of age, however, the comparison of the HFMS score of
the first evaluation with the subsequent ones in the both
groups (younger and older than 6 years of age) did not
show significant differences. Moreover, in our study we
observed a significant improvement of the HFMS scores
during the VPA treatment in the group of type II chil-
dren but not in the type III group, differently of the study
of Weihl et al [18] that showed a more efficacious of
VPA treatment in adult SMA patients than in younger
ones with a more severe phenotype.
We routinely added L-carnitine to VPA therapy as there
are numerous references to the potential benefit of this
drug in preventing or even treating a possible hepatotoxi-
city of VPA due to its interference with mitochondrial
beta-oxidation [27-30]. In addition VPA monotherapy
depletes both muscle and serum carnitine levels [30]. Side
effects were unremarkable in our study. Five patients com-
plained of weight gain, and other patients displayed
increased tremor of their fingers after six months of VPA
intake, as observed by Tsai et al [19] in one 5-years-old
child.
Conclusion
Patients with type II and III SMA submitted to treat-
ment with VPA during the period of one year had no
significant side effects, and an increased of the motor
abilities could be observed in children with type II
Table 3 Evolution of the HFMS scores in the two SMA groups (type II and III) during the VPA treatment
Evaluations
SMA 12345 p ( * )
Type II 13.6 ± 10.0 14.9 ± 11.4 15.5 ± 11.1 16.0 ± 11.2 16.9 ± 10.6 0.031
Type III 24.9 ± 3.4 24.8 ± 3.3 24.4 ± 3.5 24.4 ± 3.5 24.1 ± 3.9 0.961
p (**) 0.006 0.016 0.029 0.039 0.051
*Comparison between the first evaluation with the subsequent ones.
**Comparison between both groups (type II and III) in each evaluation.
Table 4 Evolution of the HFMS scores in the two age groups of SMA patients during the VPA treatment
Evaluations
Age 12345 p ( * )
≤ 6 years 21.5 ± 8.8 22.5 ± 9.5 22.9 ± 8.7 23.2 ± 8.3 23.5 ± 8.7 0.240
> 6 years 12.2 ± 8.8 12.7 ± 9.0 12.8 ± 9.0 13.0 ± 9.2 12.8 ± 9.1 0.922
p (**) 0.018 0.012 0.010 0.009 0.007
*Comparison between the first evaluation with the subsequent ones.
**Comparison between both groups of patients in each evaluation.
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potential alternative to alleviate the progression of the
disease.
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